But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
As the New Year begins, the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid ...
Compounded tirzepatide isn’t FDA-approved. This means there’s no guarantee it’s safe or effective. If you’re considering it, go to a safe source. Just because you can buy tirzepatide ...
Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide, support a "buy" rating for long-term investors despite current valuation metrics.